284
Participants
Start Date
March 30, 2012
Primary Completion Date
September 27, 2013
Study Completion Date
September 27, 2013
V419
Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate \[meningococcal outer membrane protein complex\], and Hepatitis B \[recombinant\] vaccine administered via 0.5 mL intramuscular injection.
PREVNAR 13®
Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).
MCC-TT
Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
MCC-CRM
Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
Hib-MCC
Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
MMR Vaccine
Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
Lead Sponsor
MCM Vaccines B.V.
INDUSTRY